KR100932071B1 - Method for preparing benzal acetophenone derivative - Google Patents
Method for preparing benzal acetophenone derivativeDownload PDFInfo
- Publication number
- KR100932071B1 KR100932071B1KR1020070094617AKR20070094617AKR100932071B1KR 100932071 B1KR100932071 B1KR 100932071B1KR 1020070094617 AKR1020070094617 AKR 1020070094617AKR 20070094617 AKR20070094617 AKR 20070094617AKR 100932071 B1KR100932071 B1KR 100932071B1
- Authority
- KR
- South Korea
- Prior art keywords
- methoxyphenyl
- hydroxy
- prop
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
- C07C49/784—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic with all keto groups bound to a non-condensed ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
- C07C49/788—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic with keto groups bound to a condensed ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
- C07C49/792—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic containing rings other than six-membered aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Translated fromKorean
Description
Translated fromKorean본 발명은 벤잘아세토페논 유도체를 효과적으로 제조하는 방법에 관한 것이다.The present invention relates to a method for effectively preparing benzalacetophenone derivatives.
벤잘아세토페논 (benzalacetophenone) 유도체는 의약, 농약 및 화장품 분야에서 광범위하게 적용되고 있는 활성성분으로서, 항염증효과, 항암효과, 항생효과 및 항바이러스효과 등이 있는 것으로 알려져있다. 최근에 이들 화합물은 항산화효과, 선충구제효과, 지질과산화 저해효과 및 아실 CoA 저해효과를 나타낼 뿐만 아니라 허혈증, 파킨슨병, 알츠하이머병, 및 헌팅톤병과 같은 정신질환에 탁월한 효과가 있는 것으로 밝혀졌다.Benzalacetophenone derivatives are widely used in medicine, pesticides and cosmetics, and are known to have anti-inflammatory, anti-cancer, antibiotic and antiviral effects. Recently, these compounds have been shown to exhibit antioxidant effects, nematode control effects, lipid peroxidation inhibitory effects and acyl CoA inhibitory effects, as well as excellent effects on mental diseases such as ischemia, Parkinson's disease, Alzheimer's disease, and Huntington's disease.
본 발명이 목적하는 하기 화학식 1로 표시되는 화합물은 플라보노이드, 페놀류의 유도체 및 벤질리덴 아세토페논 유도체의 주요 중간체로 사용될 뿐만 아니라 농약의 중간체로도 매우 유용한 것으로 알려져 있고, 이의 제조방법에 대해서도 여 러 문헌에 공지되어 있다 (문헌 [Lawrence, N. J., et al.,Bioorg. & Med. Chem. Lett., 16:5844-5848, 2006]; [Kim, D. Y., et al.,J.Med.Chem., 49:5664-5670, 2006]; 및 [Satyanarayana, M., et al.,Bioorg. &Med.Chem., 12:883-889, 2004] 참조).The compound represented by the following general formula (1), which is the object of the present invention, is not only used as a main intermediate of flavonoids, phenol derivatives and benzylidene acetophenone derivatives, but also is very useful as an intermediate of pesticides. (Lawrence, NJ, et al.,Bioorg. & Med. Chem. Lett ., 16: 5844-5848, 2006); Kim, DY, et al.,J.Med.Chem ., 49: 5664-5670, 2006; and Satyanarayana, M., et al.,Bioorg. &Med.Chem ., 12: 883-889, 2004).
상기 식에서,Where
X는 CH, CF, CCl, CI 또는 N이고;X is CH, CF, CCl, CI or N;
Y는 C 또는 N이고;Y is C or N;
R1은 수소, 하이드록시, C1-C6알킬, C1-C6알콕시, 실릴 또는 벤질이고;R1 is hydrogen, hydroxy, C1 -C6 alkyl, C1 -C6 alkoxy, silyl or benzyl;
R2및 R3는 각각 독립적으로 수소, 하이드록시, C1-C6알킬, C1-C6알킬실릴이고;R2 And R3 are each independently hydrogen, hydroxy, C1 -C6 alkyl, C1 -C6 alkylsilyl;
R4,R5 및 R6는 각각 독립적으로 수소, C1-C6알킬, 아실, 할로겐 원자, C1-C6할로알킬, C1-C6알콕시, 아미노, 나이트로 또는 산소 원자이거나, 함께 연결되어 고리화합물을 형성한다.R4 , R5 and R6 are each independently hydrogen, C1 -C6 alkyl, acyl, halogen atom, C1 -C6 haloalkyl, C1 -C6 alkoxy, amino, nitro or oxygen atom, or are linked together To form cyclic compounds.
그 중, 대표적인 제조방법은 하기 반응식 1에 나타낸 바와 같이, 화학식 4의 신남알데하이드 화합물과 화학식 5의 그리냐드 화합물을 상온에서 반응시켜 화학식 6의 알코올 화합물을 제조하고, 이를 용매 존재 하에서 산화제로 산화시키는 여러 단계의 반응을 거쳐 목적 화합물인 하기 화학식 7의 벤잘아세토페논 유도체를 제조하는 방법이다 (문헌 [Lee, H. J., et al.,Chem.Pharm.Bull., 54:377-379, 2006]; [Weber, W. M., et al.,Bioorg. &Med.Chem., 13:3811-3820, 2005]; 및 [Oh, S., et al.,Arch.Pharm.Res., 29:469-475, 2006] 참조).Among them, as shown in Scheme 1 below, a cinnamic aldehyde compound of Formula 4 and a Grignard compound of Formula 5 are reacted at room temperature to prepare an alcohol compound of Formula 6, which is oxidized with an oxidizing agent in the presence of a solvent. It is a method for preparing a benzalacetophenone derivative of the general formula (7) which is a target compound through several steps of reaction (Lee, HJ, et al.,Chem.Pharm.Bull ., 54: 377-379, 2006); [ Weber, WM, et al.,Bioorg. &Med.Chem ., 13: 3811-3820, 2005; and Oh, S., et al.,Arch.Pharm.Res ., 29: 469-475, 2006 ] Reference).
상기 식에서, R1내지 R6, X 및 Y는 상기 화학식 1에서 정의한 바와 같다.Wherein, R1 to R6 , X and Y are as defined in Formula 1 above.
그러나, 상기 반응식 1에 따른 벤잘아세토페논 유도체의 제조방법은 그리냐드 시약 및 산화제를 사용하는 등 반응조건이 격렬하고, 전체 제조공정이 복잡하고 길어 수율이 저조할 뿐만 아니라, 화학시약이 유리되어 환경에 부담이 되는 등의 문제점이 있다.However, the method for preparing benzalacetophenone derivatives according to Scheme 1 is such that using Grignard reagent and an oxidizing agent, the reaction conditions are violent, the overall manufacturing process is complicated and long, and the yield is low, and the chemical reagent is free. There is a problem such as a burden.
따라서, 보다 온화한 반응조건을 유지하면서 제조공정이 간단하고, 고순도 및 고수율로 벤잘아세토페논 유도체를 제조할 수 있는 개선된 제조방법의 개발이 요구되어 왔다.Therefore, there has been a need for the development of an improved production method which is simple in the production process while maintaining milder reaction conditions, and can produce benzalacetophenone derivatives in high purity and high yield.
따라서, 본 발명의 목적은 종래에 알려진 벤잘아세토페논 유도체의 제조방법에 있어서 보다 간단하면서도 고순도 및 고수율로 벤잘아세토페논 유도체를 제조하는 방법을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a method for producing benzalacetophenone derivatives in a simpler, higher purity and higher yield in the conventionally known method for producing benzalacetophenone derivatives.
상기 목적을 달성하기 위하여 본 발명은, 하기 화학식 2의 화합물과 화학식 3의 화합물을 용매 존재 하에서 염기와 반응시켜 하기 화학식 1의 벤잘아세토페논 유도체를 제조하는 방법을 제공한다:In order to achieve the above object, the present invention provides a method for preparing a benzalacetophenone derivative of formula 1 by reacting a compound of formula 2 and a compound of formula 3 with a base in the presence of a solvent:
<화학식 1><Formula 1>
상기 식에서,Where
X는 CH, CF, CCl, CI 또는 N이고;X is CH, CF, CCl, CI or N;
Y는 C 또는 N이고;Y is C or N;
R1은 수소, 하이드록시, C1-C6알킬, C1-C6알콕시, 실릴 또는 벤질이고;R1 is hydrogen, hydroxy, C1 -C6 alkyl, C1 -C6 alkoxy, silyl or benzyl;
R2및 R3는 각각 독립적으로 수소, 하이드록시, C1-C6알킬, C1-C6알킬실릴이고;R2 And R3 are each independently hydrogen, hydroxy, C1 -C6 alkyl, C1 -C6 alkylsilyl;
R4,R5 및 R6는 각각 독립적으로 수소, C1-C6알킬, 아실, 할로겐 원자, C1-C6할로알킬, C1-C6알콕시, 아미노, 나이트로 또는 산소 원자이거나, 함께 연결되어 고리화합물을 형성한다.R4 , R5 and R6 are each independently hydrogen, C1 -C6 alkyl, acyl, halogen atom, C1 -C6 haloalkyl, C1 -C6 alkoxy, amino, nitro or oxygen atom, or are linked together To form cyclic compounds.
본 발명에 따른 제조방법에 따르면, 의약 및 농약 그리고 화장품분야에서 광범위하게 적용되고 있는 벤잘아세토페논 유도체를 온화한 반응조건을 유지하면서 한단계 반응으로 간단하게 고순도 및 고수율로 제조할 수 있으므로, 본 발명의 방법은 상기 유도체의 공업적 제조에 유용하다.According to the production method according to the present invention, benzalacetophenone derivatives widely applied in the fields of medicine, agrochemicals and cosmetics can be easily produced in high purity and high yield in one step reaction while maintaining mild reaction conditions. The method is useful for the industrial preparation of such derivatives.
본 발명에 따른 제조방법을 개략적으로 설명하면 하기 반응식 2에 도시한 바와 같다.The manufacturing method according to the present invention is briefly described as shown in Scheme 2 below.
상기 식에서, R1내지 R6, X 및 Y는 상기에서 정의한 바와 같고, R4,R5 및 R6가 서로 연결되어 형성할 수 있는 고리화합물로는 1,3-다이옥솔, 1,4-다이옥신, 벤조이미다졸 또는 퀴녹사졸린 화합물을 들 수 있다.Wherein R1 to R6 , X and Y are as defined above, R4 , Examples of the cyclic compound in which R5 and R6 may be linked to each other include 1,3-dioxol, 1,4-dioxin, benzoimidazole, or quinoxazoline compound.
본 발명의 제조방법은 일당량의 상기 화학식 2의 알데하이드 화합물, 일당량 의 상기 화학식 3의 아세토페논 화합물 및 일당량의 염기를 알코올 용매 하에서 반응시켜 한단계 반응 (One pot)으로 간단하게 상기 화학식 1의 벤잘아세토페논 유도체를 제조하는 것을 특징으로 한다.In the preparation method of the present invention, one equivalent of the aldehyde compound of Chemical Formula 2, one equivalent of the acetophenone compound of Chemical Formula 3, and one equivalent of the base is reacted in an alcohol solvent to simplify the reaction of Chemical Formula 1 in one pot. It is characterized by preparing a benzalacetophenone derivative.
본 발명에서 출발물질로 사용되는 상기 화학식 2의 화합물로는 바닐린 (vanillin, 4-hydroxy-3-methoxybenzaldehyde), 아이소바닐린 (isovanillin, 3-hydroxy-4-methoxybenzaldehyde), 오쏘 바닐린 (O-vanillin, 2-hydroxy-3-methoxybenzaldehyde) 또는 3,4-다이메톡시벤즈알데하이드가 사용될 수 있고, 상기 화학식 3의 화합물로는 아세토페논, 트라이메틸실릴아세토페논, 3,4-메틸렌다이옥시아세토페논, 4-트라이플루오로메틸아세토페논, 3,4,5-트라이플루오로아세토페논 또는 3-플루오로-4-메톡시아세토페논이 사용될 수 있다.Compounds of the formula (2) used as starting materials in the present invention is vanillin (vanillin, 4-hydroxy-3-methoxybenzaldehyde), isovanillin (isovanillin, 3-hydroxy-4-methoxybenzaldehyde), ortho vanillin (O-vanillin, 2 -hydroxy-3-methoxybenzaldehyde) or 3,4-dimethoxybenzaldehyde, and the compound of Formula 3 may be acetophenone, trimethylsilylacetophenone, 3,4-methylenedioxyacetophenone, 4- Trifluoromethylacetophenone, 3,4,5-trifluoroacetophenone or 3-fluoro-4-methoxyacetophenone can be used.
상기 화학식 2의 화합물과 상기 화학식 3의 화합물은 1:1의 당량비로 반응시키는 것이 바람직하며, 이때 사용할 수 있는 유기용매로는 다이클로로메탄, 클로로포름, 아세토나이트릴, 다이메틸폼알데하이드, 다이메틸설폭사이드 및 이들의 혼합물, 또는 메탄올, 에탄올, 부탄올, 물 및 이들의 혼합물을 사용할 수 있으며, 메탄올을 사용하는 것이 바람직하다. 또한, 상기 반응은 0 내지 50℃에서 1 내지 200 시간 동안 수행되는 것이 바람직하다.The compound of Formula 2 and the compound of Formula 3 are preferably reacted in an equivalent ratio of 1: 1. In this case, as an organic solvent that can be used, dichloromethane, chloroform, acetonitrile, dimethylformaldehyde, and dimethyl sulfoxide And mixtures thereof, or methanol, ethanol, butanol, water and mixtures thereof, and it is preferable to use methanol. In addition, the reaction is preferably carried out at 0 to 50 ℃ for 1 to 200 hours.
또한, 본 발명에서 사용될 수 있는 염기로는 통상적으로 널리 사용되는 리튬하이드록사이드 (LiOH), 소듐하이드록사이드 (NaOH), 포타슘하이드록사이드 (KOH), 마그네슘하이드록사이드 (Mg(OH)2) 및 바륨하이드록사이드 (Ba(OH)2) 등을 들 수 있 으나, 리튬하이드록사이드 (LiOH)를 사용하는 것이 바람직하다.In addition, as the base that can be used in the present invention, lithium hydroxide (LiOH), sodium hydroxide (NaOH), potassium hydroxide (KOH), magnesium hydroxide (Mg (OH)2 ), which are commonly used widely, ) And barium hydroxide (Ba (OH)2 ), but lithium hydroxide (LiOH) is preferred.
상기 반응이 완결되면 반응 혼합액으로부터 화학식 1의 벤잘아세토페논 유도체를 당분야에서 널리 알려진 통상의 방법, 예를 들면 컬럼 크로마토그래피법, 고체석출법, 재결정법 등을 사용하여 회수할 수 있으며, 이 중 컬럼 크로마토그래피법이 가장 일반적이고 회수율이 높지만 고체석출법 또는 재결정법이 경제적으로 유용한 회수방법이라 할 수 있다.Upon completion of the reaction, the benzalacetophenone derivative of formula 1 may be recovered from the reaction mixture using conventional methods well known in the art, such as column chromatography, solid precipitation, recrystallization, and the like. Column chromatography is the most common and high recovery, but solid precipitation or recrystallization is economically useful recovery method.
본 발명에 따라 제조된 벤잘아세토페논 유도체 화합물은 상기 화학식 1에서 X 및 Y가 CH이고; R1이 수소, 하이드록시 또는 C1-C6알콕시이고; R2및 R3가 각각 독립적으로 수소 또는 C1-C6알킬이고; R4 및R5가 각각 독립적으로 수소, C1-C6알킬, 할로겐 원자, C1-C6할로알킬, C1-C6알콕시 또는 산소 원자이거나, 함께 연결되어 고리화합물을 형성하고; R6가 수소 또는 할로겐 원자인 화합물이 바람직하고, 상기 고리화합물은 1,3-다이옥솔 또는 1,4-다이옥신이 바람직하다.In the benzalacetophenone derivative compound prepared according to the present invention, in Formula 1, X and Y are CH; R1 is hydrogen, hydroxy or C1 -C6 alkoxy; R2 And R3 are each independently hydrogen or C1 -C6 alkyl; R4 and Each R5 is independently hydrogen, C1 -C6 alkyl, halogen atom, C1 -C6 haloalkyl, C1 -C6 alkoxy or oxygen atom, or are linked together to form a cyclic compound; A compound in which R6 is hydrogen or a halogen atom is preferable, and the cyclic compound is preferably 1,3-dioxol or 1,4-dioxin.
또한, 본 발명의 화학식 1에 속하는 대표적인 화합물을 하기 표 1과 같이 나타낼 수 있다.In addition, the representative compounds belonging to the general formula (1) of the present invention can be represented as shown in Table 1.
이와 같이, 화학식 2의 화합물, 화학식 3의 화합물 및 염기를 알코올 용매 하에서 한단계 반응으로 반응시켜 화학식 1의 벤잘아세토페논 화합물을 제조하는 본 발명의 방법에 의하면, 종래의 방법보다 온화한 반응조건으로도 고순도 및 고수율로 목적 화합물을 제조할 수 있다.As described above, according to the method of the present invention for preparing the benzalacetophenone compound of Formula 1 by reacting the compound of Formula 2, the compound of Formula 3, and the base in an alcoholic reaction, it is possible to obtain a high purity even under milder conditions than conventional methods. And the desired compound in high yield.
이하, 본 발명을 하기 실시예에 의거하여 좀더 상세하게 설명하고자 한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐 한정하지는 않는다.Hereinafter, the present invention will be described in more detail based on the following examples. However, the following examples are not intended to limit the invention only.
실시예 1Example 1: (: (EE)-3-(4-하이드록시-3-메톡시페닐)-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (4-hydroxy-3-methoxyphenyl) -1-phenylprop-2-en-1-one
아세토페논 (6.0 mmol)을 메탄올 (30 ㎖)에 용해시킨 후, LiOH (1.2 mmol)를 첨가하여 1시간 동안 상온에서 교반한 다음, 반응액에 바닐린 (6.0 mmol)을 첨가하고 상온에서 약 96시간 동안 교반하였다. 반응 혼합물의 용매를 감압 하에 제거한 후, 물 (35 ㎖)을 가하고 10% 염산으로 중화한 다음, 다이클로로메탄 (40 ㎖)으로 추출하여 유기층을 분리하고, 무수 황산마그네슘으로 건조하여 여과하였다. 상기 여액의 용매를 감압 하에 제거한 후, 잔사를 컬럼 크로마토그래피로 분리정제하여 표제 화합물 (수율: 90%)을 얻었다.Acetophenone (6.0 mmol) was dissolved in methanol (30 mL), followed by addition of LiOH (1.2 mmol) and stirring at room temperature for 1 hour, followed by addition of vanillin (6.0 mmol) to the reaction solution at room temperature for about 96 hours. Was stirred. After the solvent of the reaction mixture was removed under reduced pressure, water (35 mL) was added, neutralized with 10% hydrochloric acid, extracted with dichloromethane (40 mL), the organic layer was separated, dried over anhydrous magnesium sulfate, and filtered. After removing the solvent of the filtrate under reduced pressure, the residue was purified by column chromatography to give the title compound (yield: 90%).
Rf = 0.4 (20% 에틸아세테이트/헥산);Rf = 0.4 (20% ethyl acetate / hexanes);
IR (neat, NaCl) 3321, 3070, 3001, 2960, 1739, 1656, 1420, 1285, 1038 cm-1;IR (neat, NaCl) 3321, 3070, 3001, 2960, 1739, 1656, 1420, 1285, 1038 cm−1 ;
1H NMR (400 MHz, CDCl3) δ 8.02 (d,J=5.4 Hz, 2H), 7.76 (d,J=11.7 Hz, 1H), 7.58 (t,J=5.1 Hz, 1H), 7.50 (d,J=5.4 Hz, 2H), 7.38 (d,J=11.7 Hz, 1H), 7.21 (d,J=6.0 Hz, 1H), 7.14 (s, 1H), 6.96 (d,J=6.0 Hz, 1H), 5.66 (brs, 1H), 3.95 (s, 3H, OMe);1 H NMR (400 MHz, CDCl3 ) δ 8.02 (d,J = 5.4 Hz, 2H), 7.76 (d,J = 11.7 Hz, 1H), 7.58 (t,J = 5.1 Hz, 1H), 7.50 (d ,J = 5.4 Hz, 2H), 7.38 (d,J = 11.7 Hz, 1H), 7.21 (d,J = 6.0 Hz, 1H), 7.14 (s, 1H), 6.96 (d,J = 6.0 Hz, 1H ), 5.66 (brs, 1 H), 3.95 (s, 3 H, OMe);
13C NMR (100 MHz, CDCl3) δ 191.1, 149.0, 147.4, 145.7, 138.9, 132.9, 128.9, 128.8, 127.8, 123.8, 120.1, 115.4, 110.6, 56.4;13 C NMR (100 MHz, CDCl3 ) δ 191.1, 149.0, 147.4, 145.7, 138.9, 132.9, 128.9, 128.8, 127.8, 123.8, 120.1, 115.4, 110.6, 56.4;
HRMS: C16H15O3에 대한 이론치 255.1051 [M+H]+, 실측치 255.1038.HRMS: calc. For C16 H15 O3 255.1051 [M + H]+ , found 255.1038.
실시예 2Example 2::(E(E)-3-(4-하이드록시-3-메톡시페닐)-1-[(3,4-메틸렌다이옥시페닐)]-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (4-hydroxy-3-methoxyphenyl) -1-[(3,4-methylenedioxyphenyl)]-1-phenylprop-2-en-1-one
아세토페논 대신 3,4-메틸렌다이옥시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 75%)을 얻었다.The title compound (yield: 75%) was obtained in the same manner as in Example 1, except that 3,4-methylenedioxyacetophenone was used instead of acetophenone.
Rf = 0.3 (30% 에틸아세테이트/헥산);Rf = 0.3 (30% ethyl acetate / hexanes);
IR (neat, NaCl) 3349, 3007, 2955, 2876, 1645, 1554, 1477, 1243, 1186, 1045 cm-1;IR (neat, NaCl) 3349, 3007, 2955, 2876, 1645, 1554, 1477, 1243, 1186, 1045 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 7.11-6.72 (m, 6H), 6.59 (dd,J=7.5, 7.0 Hz, 1H), 6.38 (dd,J=7.0, 7.0 Hz, 1H), 6.05 (s, 2H), 3.88 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 7.11-6.72 (m, 6H), 6.59 (dd,J = 7.5, 7.0 Hz, 1H), 6.38 (dd,J = 7.0, 7.0 Hz, 1H), 6.05 ( s, 2H), 3.88 (s, 3H, OMe);
13C NMR (125 MHz, CDCl3) δ 188.9, 151.1, 147.0, 146.3, 145.7, 138.3, 133.5, 127.9, 126.5, 125.4, 122.1, 121.4, 120.5, 112.1, 102.5, 55.9;13 C NMR (125 MHz, CDCl3 ) δ 188.9, 151.1, 147.0, 146.3, 145.7, 138.3, 133.5, 127.9, 126.5, 125.4, 122.1, 121.4, 120.5, 112.1, 102.5, 55.9;
HRMS: C17H15O5에 대한 이론치 299.0919 [M+H]+, 실측치 299.0928.HRMS: calcd for C17 H15 O5 299.0919 [M + H]+ , found 299.0928.
실시예 3Example 3: (: (EE)-3-(4-하이드록시-3-메톡시페닐)-1-(4-트라이플루오로메틸페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (4-hydroxy-3-methoxyphenyl) -1- (4-trifluoromethylphenyl) -1-prop-2-en-1-one
아세토페논 대신 4-트라이플루오로메틸아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 71%)을 얻었다.The title compound (yield: 71%) was obtained in the same manner as in Example 1, except that 4-trifluoromethylacetophenone was used instead of acetophenone.
Rf = 0.3 (30% 에틸아세테이트/헥산);Rf = 0.3 (30% ethyl acetate / hexanes);
IR (neat, NaCl) 3384, 3011, 2964, 2876, 1658, 1585, 1512, 1452, 1323, 1272, 1125, 1033 cm-1;IR (neat, NaCl) 3384, 3011, 2964, 2876, 1658, 1585, 1512, 1452, 1323, 1272, 1125, 1033 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 8.09 (d,J=8.0 Hz, 2H), 7.76 (dd,J=6.5, 6.5 Hz, 3H), 7.34 (d,J=16.0, Hz, 1H), 7.23 (dd,J=1.5, 1.5 Hz, 1H), 7.15 (d,J=1.5 Hz, 1H), 6.97 (d,J=8.0 Hz, 1H), 3.96 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 8.09 (d,J = 8.0 Hz, 2H), 7.76 (dd,J = 6.5, 6.5 Hz, 3H), 7.34 (d,J = 16.0, Hz, 1H), 7.23 (dd,J = 1.5, 1.5 Hz, 1H), 7.15 (d,J = 1.5 Hz, 1H), 6.97 (d,J = 8.0 Hz, 1H), 3.96 (s, 3H, OMe);
13C NMR (125 MHz, CDCl3) δ 189.6, 149.4, 146.1, 145.9, 145.0, 138.5, 133.2, 128.3, 126.8, 124.1, 120.0, 115.6, 111.4, 56.1;13 C NMR (125 MHz, CDCl3 ) δ 189.6, 149.4, 146.1, 145.9, 145.0, 138.5, 133.2, 128.3, 126.8, 124.1, 120.0, 115.6, 111.4, 56.1;
HRMS: C17H13F3O3에 대한 이론치 345.0714 [M+Na]+, 실측치 345.0725.HRMS: calcd for C17 H13 F3 O3 345.0714 [M + Na]+ , found 345.0725.
실시예 4Example 4::(E(E)-3-(4-하이드록시-3-메톡시페닐)-1-(3,4,5-트라이플루오로페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (4-hydroxy-3-methoxyphenyl) -1- (3,4,5-trifluorophenyl) -1-prop-2-en-1-one
아세토페논 대신 3,4,5-트라이플루오로아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 78%)을 얻었다.The title compound (yield: 78%) was obtained in the same manner as in Example 1, except that 3,4,5-trifluoroacetophenone was used instead of acetophenone.
Rf = 0.3 (30% 에틸아세테이트/헥산);Rf = 0.3 (30% ethyl acetate / hexanes);
IR (neat, NaCl) 3350, 3005, 2985, 2858, 1657, 1550, 1448, 1262, 1153, 1081 cm-1;IR (neat, NaCl) 3350, 3005, 2985, 2858, 1657, 1550, 1448, 1262, 1153, 1081 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 7.83 (d,J=16.0 Hz, 1H), 7.66 (t,J=8.0 Hz, 2H), 7.22 (d,J=16.0 Hz, 1H), 7.20 (d,J=8.5 Hz, 1H), 7.15 (s, 1H), 6.93 (d,J=8.0 Hz, 1H), 3.90 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 7.83 (d,J = 16.0 Hz, 1H), 7.66 (t,J = 8.0 Hz, 2H), 7.22 (d,J = 16.0 Hz, 1H), 7.20 (d ,J = 8.5 Hz, 1H), 7.15 (s, 1H), 6.93 (d,J = 8.0 Hz, 1H), 3.90 (s, 3H, OMe);
13C NMR (125 MHz, CDCl3) δ 187.3, 151.0, 148.2, 146.5, 132.2, 128.3, 122.9, 121.7, 119.3, 113.1, 112.2, 111.9, 55.8;13 C NMR (125 MHz, CDCl3 ) δ 187.3, 151.0, 148.2, 146.5, 132.2, 128.3, 122.9, 121.7, 119.3, 113.1, 112.2, 111.9, 55.8;
HRMS: C16H12F3O3에 대한 이론치 309.0739 [M+H]+, 실측치 309.0745.HRMS: calcd for C16 H12 F3 O3 309.0739 [M + H]+ , found 309.0745.
실시예 5Example 5: (: (EE)-1-(3-플루오로-4-메톡시페닐)-3-(4-하이드록시-3-메톡시페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -1- (3-fluoro-4-methoxyphenyl) -3- (4-hydroxy-3-methoxyphenyl) -1-prop-2-en-1-one
아세토페논 대신 3-플루오로-4-메톡시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 82%)을 얻었다.The title compound (yield: 82%) was obtained in the same manner as in Example 1, except that 3-fluoro-4-methoxyacetophenone was used instead of acetophenone.
Rf = 0.3 (40% 에틸아세테이트/헥산);Rf = 0.3 (40% ethyl acetate / hexanes);
IR (neat, NaCl) 3359, 2987, 2875, 1662, 1578, 1455, 1278, 1164, 1086 cm-1;IR (neat, NaCl) 3359, 2987, 2875, 1662, 1578, 1455, 1278, 1164, 1086 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 7.85-7.72 (m, 3H), 7.33 (d,J=16.0 Hz, 1H), 7.15 (d,J=8.5 Hz, 1H), 7.13 (s, 1H), 7.04 (t,J=8.5 Hz, 1H), 6.91 (d,J=8.0 Hz, 1H), 3.96 (s, 3H), 3.91 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 7.85-7.72 (m, 3H), 7.33 (d,J = 16.0 Hz, 1H), 7.15 (d,J = 8.5 Hz, 1H), 7.13 (s, 1H) , 7.04 (t,J = 8.5 Hz, 1H), 6.91 (d,J = 8.0 Hz, 1H), 3.96 (s, 3H), 3.91 (s, 3H, OMe);
13C NMR (125 MHz, CDCl3) δ 189.4, 150.3, 148.7, 145.2, 132.4, 129.6, 124.9, 123.1, 121.8, 119.5, 115.3, 113.2, 111.8, 56.8, 55.9;13 C NMR (125 MHz, CDCl3 ) δ 189.4, 150.3, 148.7, 145.2, 132.4, 129.6, 124.9, 123.1, 121.8, 119.5, 115.3, 113.2, 111.8, 56.8, 55.9;
HRMS: C17H16FO4에 대한 이론치 303.1033 [M+H]+, 실측치 303.1020.HRMS: calc. For C17 H16 FO4 303.1033 [M + H]+ , found 303.1020.
실시예 6Example 6: (: (EE)-3-(3-하이드록시-4-메톡시페닐)-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (3-hydroxy-4-methoxyphenyl) -1-phenylprop-2-en-1-one
바닐린 대신 아이소바닐린을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 87%)을 얻었다.The title compound (yield: 87%) was obtained in the same manner as in Example 1, except that isoaniline was used instead of vanillin.
Rf = 0.3 (30% 에틸아세테이트/헥산);Rf = 0.3 (30% ethyl acetate / hexanes);
IR (neat, NaCl) 3348, 2983, 1684, 1545, 1468, 1280, 1144, 1081 cm-1;IR (neat, NaCl) 3348, 2983, 1684, 1545, 1468, 1280, 1144, 1081 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 8.01 (d,J=8.2 Hz, 2H, Ar H), 7.75 (d,J=15.6 Hz, 1H, vinyl), 7.68-7.18 (m, 5H, Ar H), 7.12 (d,J=8.3 Hz, 1H, Ar H), 6.87 (d,J=8.3 Hz, 1H, vinyl), 5.77 (s, 1H, OH), 3.94 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 8.01 (d,J = 8.2 Hz, 2H, Ar H), 7.75 (d,J = 15.6 Hz, 1H, vinyl), 7.68-7.18 (m, 5H, Ar H ), 7.12 (d,J = 8.3 Hz, 1H, Ar H), 6.87 (d,J = 8.3 Hz, 1H, vinyl), 5.77 (s, 1H, OH), 3.94 (s, 3H, OMe);
HRMS: C16H15O4에 대한 이론치 255.1021 [M+H]+, 실측치 255.1035.HRMS: calc. For C16 H15 O4 255.1021 [M + H]+ , found 255.1035.
실시예 7Example 7: (: (EE)-3-(3-하이드록시-4-메톡시페닐)-1-[(3,4-메틸렌다이옥시페닐)]-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (3-hydroxy-4-methoxyphenyl) -1-[(3,4-methylenedioxyphenyl)]-1-phenylprop-2-en-1-one
바닐린 대신 아이소바닐린을 사용하고, 아세토페논 대신 3,4-메틸렌다이옥시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 70%)을 얻었다.The title compound (yield: 70%) was obtained in the same manner as in Example 1, except that isoaniline was used instead of vanillin and 3,4-methylenedioxyacetophenone was used instead of acetophenone.
Rf = 0.3 (40% 에틸아세테이트/헥산);Rf = 0.3 (40% ethyl acetate / hexanes);
IR (neat, NaCl) 3340, 2969, 1671, 1460, 1265, 1176, 1055 cm-1;IR (neat, NaCl) 3340, 2969, 1671, 1460, 1265, 1176, 1055 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 7.73 (d,J=15.5 Hz, 1H, vinyl), 7.64 (dd,J=1.7, 1.7 Hz, 1H, Ar H), 7.52 (d,J=1.6 Hz, 1H, Ar H), 7.37 (d,J=15.5 Hz, 1H, vinyl), 7.32-7.26 (m, 1H, Ar H), 7.13 (dd,J=2.0, 2.0 Hz 1H, Ar H), 6.89 (dd,J=3.8, 6.0 Hz, 2H, Ar H), 6.05 (s, 2H, CH2), 5.69 (s, 1H, OH), 3.95 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 7.73 (d,J = 15.5 Hz, 1H, vinyl), 7.64 (dd,J = 1.7, 1.7 Hz, 1H, Ar H), 7.52 (d,J = 1.6 Hz , 1H, Ar H), 7.37 (d,J = 15.5 Hz, 1H, vinyl), 7.32-7.26 (m, 1H, Ar H), 7.13 (dd,J = 2.0, 2.0 Hz 1H, Ar H), 6.89 (dd,J = 3.8, 6.0 Hz, 2H, Ar H), 6.05 (s, 2H, CH2 ), 5.69 (s, 1H, OH), 3.95 (s, 3H, OMe);
HRMS: C17H15O3에 대한 이론치 299.0919 [M+H]+, 실측치 299.0910.HRMS: calcd for C17 H15 O3 299.0919 [M + H]+ , found 299.0910.
실시예 8Example 8: (: (EE)-3-(3-하이드록시-4-메톡시페닐)-1-(4-트라이플루오로메틸페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (3-hydroxy-4-methoxyphenyl) -1- (4-trifluoromethylphenyl) -1-prop-2-en-1-one
바닐린 대신 아이소바닐린을 사용하고, 아세토페논 대신 4-트라이플루오로메틸아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 70%)을 얻었다.The title compound (yield: 70%) was obtained in the same manner as in Example 1, except that isovanillin was used instead of vanillin and 4-trifluoromethylacetophenone was used instead of acetophenone.
Rf = 0.3 (30% 에틸아세테이트/헥산);Rf = 0.3 (30% ethyl acetate / hexanes);
IR (neat, NaCl) 3379, 2975, 1662, 1556, 1467, 1217, 1145, 1056 cm-1;IR (neat, NaCl) 3379, 2975, 1662, 1556, 1467, 1217, 1145, 1056 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 8.01 (d,J=8.3 Hz, 2H, Ar H), 7.76 (dd,J=7.5, 7.5 Hz, 3H, Ar H, vinyl), 7.34 (d,J=15.8, Hz, 1H, vinyl), 7.23 (dd,J=1.5, 1.5 Hz, 1H, Ar H ), 7.15 (d,J=1.5 Hz, 1H, Ar H), 6.97 (d,J=8.0 Hz, 1H, Ar H), 5.37 (s, 1H, OH), 3.96 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 8.01 (d,J = 8.3 Hz, 2H, Ar H), 7.76 (dd,J = 7.5, 7.5 Hz, 3H, Ar H, vinyl), 7.34 (d,J = 15.8, Hz, 1H, vinyl), 7.23 (dd,J = 1.5, 1.5 Hz, 1H, Ar H), 7.15 (d,J = 1.5 Hz, 1H, Ar H), 6.97 (d,J = 8.0 Hz , 1H, Ar H), 5.37 (s, 1H, OH), 3.96 (s, 3H, OMe);
HRMS: C17H14F3O3에 대한 이론치 323.0895 [M+H]+, 실측치 323.0880.HRMS: calc. For C17 H14 F3 O3 323.0895 [M + H]+ , found 323.0880.
실시예 9Example 9: (: (EE)-3-(3-하이드록시-4-메톡시페닐)-1-(3,4,5-트라이플루오로페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (3-hydroxy-4-methoxyphenyl) -1- (3,4,5-trifluorophenyl) -1-prop-2-en-1-one
바닐린 대신 아이소바닐린을 사용하고, 아세토페논 대신 3,4,5-트라이플루오로아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 75%)을 얻었다.The title compound (yield: 75%) was obtained in the same manner as in Example 1, except that isoaniline was used instead of vanillin and 3,4,5-trifluoroacetophenone was used instead of acetophenone.
Rf = 0.3 (30% 에틸아세테이트/헥산);Rf = 0.3 (30% ethyl acetate / hexanes);
IR (neat, NaCl) 3336, 2978, 1678, 1456, 1268, 1122, 1065 cm-1;IR (neat, NaCl) 3336, 2978, 1678, 1456, 1268, 1122, 1065 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 7.75 (d,J=15.5 Hz, 1H, vinyl), 7.60 (d,J=8.3 Hz, 2H, Ar H), 7.36-7.16 (m, 2H, Ar H), 7.14 (d,J=8.4 Hz, 1H, Ar H), 6.87 (d,J=8.5 Hz, 1H, vinyl), 5.75 (s, 1H, OH), 3.95 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 7.75 (d,J = 15.5 Hz, 1H, vinyl), 7.60 (d,J = 8.3 Hz, 2H, Ar H), 7.36-7.16 (m, 2H, Ar H ), 7.14 (d,J = 8.4 Hz, 1H, Ar H), 6.87 (d,J = 8.5 Hz, 1H, vinyl), 5.75 (s, 1H, OH), 3.95 (s, 3H, OMe);
HRMS: C16H12F3O3에 대한 이론치 309.0739 [M+H]+, 실측치 309.0751.HRMS: calcd for C16 H12 F3 O3 309.0739 [M + H]+ , found 309.0751.
실시예 10Example 10: (: (EE)-1-(3-플루오로-4-메톡시페닐)-3-(3-하이드록시-4-메톡시페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -1- (3-fluoro-4-methoxyphenyl) -3- (3-hydroxy-4-methoxyphenyl) -1-prop-2-en-1-one
바닐린 대신 아이소바닐린을 사용하고, 아세토페논 대신 3-플루오로-4-메톡시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 80%)을 얻었다.The title compound (yield: 80%) was obtained in the same manner as in Example 1, except that isovanillin was used instead of vanillin and 3-fluoro-4-methoxyacetophenone was used instead of acetophenone.
Rf = 0.3 (25% 에틸아세테이트/헥산);Rf = 0.3 (25% ethyl acetate / hexanes);
IR (neat, NaCl) 3355, 2976, 1682, 1458, 1276, 1120, 1076 cm-1;IR (neat, NaCl) 3355, 2976, 1682, 1458, 1276, 1120, 1076 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 7.95-7.78 (m, 2H, Ar H), 7.76 (d,J=15.5 Hz, 1H, vinyl), 7.39-7.27 (m, 2H, Ar H), 7.15-7.04 (m, 2H, Ar H), 6.84 (d,J=4.8 Hz, 1H, vinyl), 5.77 (s, 1H, OH), 3.97 (s, 3H, OMe), 3.94 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 7.95-7.78 (m, 2H, Ar H), 7.76 (d,J = 15.5 Hz, 1H, vinyl), 7.39-7.27 (m, 2H, Ar H), 7.15 -7.04 (m, 2H, Ar H), 6.84 (d,J = 4.8 Hz, 1H, vinyl), 5.77 (s, 1H, OH), 3.97 (s, 3H, OMe), 3.94 (s, 3H, OMe );
HRMS: C17H16FO4에 대한 이론치 303.1033 [M+H]+, 실측치 303.1045.HRMS: calc. For C17 H16 FO4 303.1033 [M + H]+ , found 303.1045.
실시예 11Example 11: (: (EE)-3-(2-하이드록시-3-메톡시페닐)-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (2-hydroxy-3-methoxyphenyl) -1-phenylprop-2-en-1-one
바닐린 대신 오쏘바닐린을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 89%)을 얻었다.The title compound (yield: 89%) was obtained by the same method as Example 1, except that orthovanillin was used instead of vanillin.
Rf = 0.3 (30% 에틸아세테이트/헥산);Rf = 0.3 (30% ethyl acetate / hexanes);
IR (neat, NaCl) 3340, 2987, 1670, 1448, 1285, 1122, 1084 cm-1;IR (neat, NaCl) 3340, 2987, 1670, 1448, 1285, 1122, 1084 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 8.12 (d,J=15.8 Hz, 1H, vinyl), 8.00 (d,J=6.9 Hz, 2H, Ar H), 7.73 (d,J=15.8 Hz, 1H, vinyl), 7.65-7.42 (m, 3H, Ar H), 7.23 (d,J=7.8 Hz, 1H, Ar H), 6.90 (d,J=8.5 Hz, 1H, Ar H), 6.79 (d,J=7.8 Hz, 1H, Ar H), 4.66 (s, 1H, OH), 3.84 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 8.12 (d,J = 15.8 Hz, 1H, vinyl), 8.00 (d,J = 6.9 Hz, 2H, Ar H), 7.73 (d,J = 15.8 Hz, 1H , vinyl), 7.65-7.42 (m, 3H, Ar H), 7.23 (d,J = 7.8 Hz, 1H, Ar H), 6.90 (d,J = 8.5 Hz, 1H, Ar H), 6.79 (d,J = 7.8 Hz, 1H, Ar H), 4.66 (s, 1H, OH), 3.84 (s, 3H, OMe);
HRMS: C16H15O3에 대한 이론치 255.1021 [M+H]+, 실측치 255.1012.HRMS: calcd for C16 H15 O3 255.1021 [M + H]+ , found 255.1012.
실시예 12Example 12: (: (EE)-3-(2-하이드록시-3-메톡시페닐)-1-[(3,4-메틸렌다이옥시페닐)]-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (2-hydroxy-3-methoxyphenyl) -1-[(3,4-methylenedioxyphenyl)]-1-phenylprop-2-en-1-one
바닐린 대신 오쏘바닐린을 사용하고, 아세토페논 대신 3,4-메틸렌다이옥시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 68%)을 얻었다.The title compound (yield: 68%) was obtained in the same manner as in Example 1, except that orthovanillin was used instead of vanillin and 3,4-methylenedioxyacetophenone was used instead of acetophenone.
Rf = 0.3 (40% 에틸아세테이트/헥산);Rf = 0.3 (40% ethyl acetate / hexanes);
IR (neat, NaCl) 3345, 2977, 1675, 1465, 1248, 1166, 1045 cm-1;IR (neat, NaCl) 3345, 2977, 1675, 1465, 1248, 1166, 1045 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 7.73 (d,J=15.6 Hz, 1H, vinyl), 7.65 (d,J=7.8 Hz, 1H, Ar H), 7.61 (d,J=4.8 Hz, 1H, Ar H), 7.31 (d,J=15.6 Hz, 1H, vinyl), 7.22 (d,J=3.2 Hz, 1H, Ar H), 6.92 (dd,J=4.8, 1.6 Hz, 1H, Ar H), 6.88-6.79 (m, 2H, Ar H), 6.05 (s, 2H, CH2), 5.78 (s, 1H, OH), 3.88 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 7.73 (d,J = 15.6 Hz, 1H, vinyl), 7.65 (d,J = 7.8 Hz, 1H, Ar H), 7.61 (d,J = 4.8 Hz, 1H , Ar H), 7.31 (d,J = 15.6 Hz, 1H, vinyl), 7.22 (d,J = 3.2 Hz, 1H, Ar H), 6.92 (dd,J = 4.8, 1.6 Hz, 1H, Ar H) , 6.88-6.79 (m, 2H, Ar H), 6.05 (s, 2H, CH2 ), 5.78 (s, 1H, OH), 3.88 (s, 3H, OMe);
HRMS: C17H15O3에 대한 이론치 299.0919 [M+H]+, 실측치 299.0936.HRMS: calcd for C17 H15 O3 299.0919 [M + H]+ , found 299.0936.
실시예 13Example 13: (: (EE)-3-(2-하이드록시-3-메톡시페닐)-1-(4-트라이플루오로메틸페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (2-hydroxy-3-methoxyphenyl) -1- (4-trifluoromethylphenyl) -1-prop-2-en-1-one
바닐린 대신 오쏘바닐린을 사용하고, 아세토페논 대신 4-트라이플루오로메틸아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 75%)을 얻었다.The title compound (yield: 75%) was obtained in the same manner as in Example 1, except that orthovanillin was used instead of vanillin and 4-trifluoromethylacetophenone was used instead of acetophenone.
Rf = 0.3 (30% 에틸아세테이트/헥산);Rf = 0.3 (30% ethyl acetate / hexanes);
IR (neat, NaCl) 3350, 2979, 1675, 1458, 1244, 1065 cm-1;IR (neat, NaCl) 3350, 2979, 1675, 1458, 1244, 1065 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 7.98 (d,J=8.0 Hz, 2H, Ar H), 7.55 (d,J=15.8 Hz, 1H, vinyl), 7.51 (d,J=7.5 Hz, 2H, Ar H), 7.34 (d,J=15.8, Hz, 1H, vinyl), 7.22 (dd,J=2.5, 2.5 Hz, 1H, Ar H), 7.11 (d,J=3.5 Hz, 1H, Ar H), 6.94 (d,J=8.0 Hz, 1H, Ar H), 5.45 (s, 1H, OH), 3.93 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 7.98 (d,J = 8.0 Hz, 2H, Ar H), 7.55 (d,J = 15.8 Hz, 1H, vinyl), 7.51 (d,J = 7.5 Hz, 2H , Ar H), 7.34 (d,J = 15.8, Hz, 1H, vinyl), 7.22 (dd,J = 2.5, 2.5 Hz, 1H, Ar H), 7.11 (d,J = 3.5 Hz, 1H, Ar H ), 6.94 (d,J = 8.0 Hz, 1H, Ar H), 5.45 (s, 1H, OH), 3.93 (s, 3H, OMe);
HRMS: C17H14F3O3에 대한 이론치 323.0895 [M+H]+, 실측치 323.0872.HRMS: calc. For C17 H14 F3 O3 323.0895 [M + H]+ , found 323.0872.
실시예 14Example 14: (: (EE)-3-(2-하이드록시-3-메톡시페닐)-1-(3,4,5-트라이플루오로페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (2-hydroxy-3-methoxyphenyl) -1- (3,4,5-trifluorophenyl) -1-prop-2-en-1-one
바닐린 대신 오쏘바닐린을 사용하고, 아세토페논 대신 3,4,5-트라이플루오로아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 77%)을 얻었다.The title compound (yield: 77%) was obtained in the same manner as in Example 1, except that orthovanillin was used instead of vanillin and 3,4,5-trifluoroacetophenone was used instead of acetophenone.
Rf = 0.3 (30% 에틸아세테이트/헥산);Rf = 0.3 (30% ethyl acetate / hexanes);
IR (neat, NaCl) 3405, 2987, 1675, 1540, 1455, 1247, 1130, 1060 cm-1;IR (neat, NaCl) 3405, 2987, 1675, 1540, 1455, 1247, 1130, 1060 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 7.99 (d,J=15.5 Hz, 1H, vinyl), 7.76 (d,J=7.5 Hz, 2H, Ar H), 7.34 (d,J=15.5, Hz, 1H, vinyl), 7.23 (dd,J=3.5, 3.5 Hz, 1H, Ar H), 7.18 (d,J=6.5 Hz, 1H, Ar H), 6.93 (d,J=7.5 Hz, 1H, Ar H), 5.54 (s, 1H, OH), 3.91 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 7.99 (d,J = 15.5 Hz, 1H, vinyl), 7.76 (d,J = 7.5 Hz, 2H, Ar H), 7.34 (d,J = 15.5, Hz, 1H, vinyl), 7.23 (dd,J = 3.5, 3.5 Hz, 1H, Ar H), 7.18 (d,J = 6.5 Hz, 1H, Ar H), 6.93 (d,J = 7.5 Hz, 1H, Ar H ), 5.54 (s, 1H, OH), 3.91 (s, 3H, OMe);
HRMS: C16H12F3O3에 대한 이론치 309.0739 [M+H]+, 실측치 309.0722.HRMS: calcd for C16 H12 F3 O3 309.0739 [M + H]+ , found 309.0722.
실시예 15Example 15: (: (EE)-1-(3-플루오로-4-메톡시페닐)-3-(2-하이드록시-3-메톡시페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -1- (3-fluoro-4-methoxyphenyl) -3- (2-hydroxy-3-methoxyphenyl) -1-prop-2-en-1-one
바닐린 대신 오쏘바닐린을 사용하고, 아세토페논 대신 3-플루오로-4-메톡시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 81%)을 얻었다.The title compound (yield: 81%) was obtained in the same manner as in Example 1, except that orovanillin was used instead of vanillin and 3-fluoro-4-methoxyacetophenone was used instead of acetophenone.
Rf = 0.3 (25% 에틸아세테이트/헥산);Rf = 0.3 (25% ethyl acetate / hexanes);
IR (neat, NaCl) 3352, 2979, 1687, 1466, 1285, 1122, 1084 cm-1;IR (neat, NaCl) 3352, 2979, 1687, 1466, 1285, 1122, 1084 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 8.20 (d,J=15.5 Hz, 1H, vinyl), 8.11-8.06 (m, 2H, Ar H), 7.96 (d,J=15.5 Hz, 1H, vinyl), 7.41 (dd,J=3.5, 3.5 Hz, 1H, Ar H), 7.22 (t,J=8.4 Hz, 1H, Ar H), 7.16-7.03 (m, 2H, Ar H), 6.56 (s, 1H, OH), 4.21 (s, 3H, OMe), 4.17 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 8.20 (d,J = 15.5 Hz, 1H, vinyl), 8.11-8.06 (m, 2H, Ar H), 7.96 (d,J = 15.5 Hz, 1H, vinyl) , 7.41 (dd,J = 3.5, 3.5 Hz, 1H, Ar H), 7.22 (t,J = 8.4 Hz, 1H, Ar H), 7.16-7.03 (m, 2H, Ar H), 6.56 (s, 1H , OH), 4.21 (s, 3H, OMe), 4.17 (s, 3H, OMe);
HRMS: C17H16FO4에 대한 이론치 303.1033 [M+H]+, 실측치 303.1053.HRMS: calc. For C17 H16 FO4 303.1033 [M + H]+ , found 303.1053.
실시예 16Example 16: (: (EE)-3-(3,4-다이메톡시페닐)-1-[(3,4-메틸렌다이옥시페닐)]-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (3,4-dimethoxyphenyl) -1-[(3,4-methylenedioxyphenyl)]-1-phenylprop-2-en-1-one
바닐린 대신 3,4-다이메톡시벤즈알데하이드를 사용하고, 아세토페논 대신 3,4-메틸렌다이옥시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 73%)을 얻었다.The title compound (yield: 73%) was obtained in the same manner as in Example 1, except that 3,4-dimethoxybenzaldehyde was used instead of vanillin and 3,4-methylenedioxyacetophenone was used instead of acetophenone. Got it.
Rf = 0.3 (30% 에틸아세테이트/헥산);Rf = 0.3 (30% ethyl acetate / hexanes);
IR (neat, NaCl) 3305, 2965, 1681, 1455, 1240, 1033 cm-1;IR (neat, NaCl) 3305, 2965, 1681, 1455, 1240, 1033 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 7.73 (d,J=15.5 Hz, 1H, vinyl), 7.63 (dd,J=1.7, 1.7 Hz, 1H, Ar H), 7.52 (d,J=1.6 Hz, 1H, Ar H), 7.30 (d,J=15.5 Hz, 1H, vinyl), 7.21 (d,J=2.5, 2.5 Hz, 1H, Ar H), 7.15 (d,J=1.8 Hz, 1H, Ar H), 6.89 (d,J=7.5 Hz, 2H, Ar H), 6.05 (s, 2H, CH2), 3.95 (s, 3H, OMe), 3.93 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 7.73 (d,J = 15.5 Hz, 1H, vinyl), 7.63 (dd,J = 1.7, 1.7 Hz, 1H, Ar H), 7.52 (d,J = 1.6 Hz , 1H, Ar H), 7.30 (d,J = 15.5 Hz, 1H, vinyl), 7.21 (d,J = 2.5, 2.5 Hz, 1H, Ar H), 7.15 (d,J = 1.8 Hz, 1H, Ar H), 6.89 (d,J = 7.5 Hz, 2H, Ar H), 6.05 (s, 2H, CH2 ), 3.95 (s, 3H, OMe), 3.93 (s, 3H, OMe);
HRMS: C18H17O5에 대한 이론치 313.1076 [M+H]+, 실측치 313.1092.HRMS: calc. For C18 H17 O5 313.1076 [M + H]+ , found 313.1092.
실시예 17Example 17: (: (EE)-3-(3,4-다이메톡시페닐)-1-(3-플루오로-4-메톡시페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (3,4-dimethoxyphenyl) -1- (3-fluoro-4-methoxyphenyl) -1-prop-2-en-1-one
바닐린 대신 3,4-다이메톡시벤즈알데하이드를 사용하고, 아세토페논 대신 3-플루오로-4-메톡시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 89%)을 얻었다.The title compound (yield: 89% in the same manner as in Example 1) except that 3,4-dimethoxybenzaldehyde was used instead of vanillin and 3-fluoro-4-methoxyacetophenone was used instead of acetophenone. )
Rf = 0.3 (30% 에틸아세테이트/헥산);Rf = 0.3 (30% ethyl acetate / hexanes);
IR (neat, NaCl) 3030, 2988, 1697, 1512, 1264, 1120, 1064 cm-1;IR (neat, NaCl) 3030, 2988, 1697, 1512, 1264, 1120, 1064 cm−1 ;
1H NMR (500 MHz, CDCl3) δ 7.68 (d,J=15.6 Hz, 1H, vinyl), 7.65-7.41 (m, 2H, Ar H), 7.36 (d,J=15.6 Hz, 1H, vinyl), 7.21 (dd,J=2.5, 2.5 Hz, 1H, Ar H), 7.10 (dJ=8.4 Hz, 1H, Ar H), 7.06-6.91 (m, 2H, Ar H), 3.91 (s, 6H, 2 × OMe), 3.83 (s, 3H, OMe);1 H NMR (500 MHz, CDCl3 ) δ 7.68 (d,J = 15.6 Hz, 1H, vinyl), 7.65-7.41 (m, 2H, Ar H), 7.36 (d,J = 15.6 Hz, 1H, vinyl) , 7.21 (dd,J = 2.5, 2.5 Hz, 1H, Ar H), 7.10 (dJ = 8.4 Hz, 1H, Ar H), 7.06-6.91 (m, 2H, Ar H), 3.91 (s, 6H, 2 x OMe), 3.83 (s, 3H, OMe);
HRMS: C18H18FO4에 대한 이론치 317.1189 [M+H]+, 실측치 317.1196.HRMS: calc. For C18 H18 FO4 317.1189 [M + H]+ , found 317.1196.
Claims (8)
Translated fromKorean
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070094617AKR100932071B1 (en) | 2007-09-18 | 2007-09-18 | Method for preparing benzal acetophenone derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070094617AKR100932071B1 (en) | 2007-09-18 | 2007-09-18 | Method for preparing benzal acetophenone derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20090029410A KR20090029410A (en) | 2009-03-23 |
| KR100932071B1true KR100932071B1 (en) | 2009-12-15 |
Family
ID=40696135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020070094617AExpired - Fee RelatedKR100932071B1 (en) | 2007-09-18 | 2007-09-18 | Method for preparing benzal acetophenone derivative |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100932071B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101252033B1 (en)* | 2010-08-18 | 2013-04-15 | 연세대학교 산학협력단 | 4-Hydroxy-3-methoxyphenyl-2-propenone derivatives, preparation method thereof and antioxidant composition comprising the same |
- 2007
- 2007-09-18KRKR1020070094617Apatent/KR100932071B1/ennot_activeExpired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| Bioorg. Med. Chem. 13, pp. 3811-3820, 2005* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090029410A (en) | 2009-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5068364A (en) | Chalcone derivatives and process for producing the same | |
| CA2658652C (en) | Novel process for the synthesis of (e)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | |
| WO2012009818A1 (en) | Protected aldehydes for use as intermediates in chemical syntheses, and processes for their preparation | |
| WO2001060774A1 (en) | Synthesis of resveratrol | |
| CN101323567B (en) | Process for preparing cinnamate and derivates thereof | |
| KR100932071B1 (en) | Method for preparing benzal acetophenone derivative | |
| JP6702623B2 (en) | Method for preparing compounds such as 3-arylbutanal useful in the synthesis of medetomidine | |
| CN101977883A (en) | Process for production of 2-hydroxyaryl aldehyde compound | |
| Shin et al. | Convenient synthesis of 3-aminocoumarin derivatives by the condensation of 1, 4-diacetyl-or 3-substituent-2, 5-piperazinediones with various salicylaldehyde derivatives. | |
| Son et al. | A simple synthesis of nordihydroguaiaretic acid and its analogues | |
| CN108689829B (en) | Preparation method of salvianolic acid F | |
| EP0457912A1 (en) | METHOD FOR THE PREPARATION OF $g(a),$g(b)-UNSATURATED KETONES | |
| JPH0616600A (en) | Method for producing phenoxyethylamines | |
| Li et al. | An efficient synthesis of resveratrol and a hydroxyl derivative via the Perkin reaction: cis to trans isomerisation in a demethylation process | |
| SU1098210A1 (en) | Method of producing unsaturated ketones | |
| KR100783626B1 (en) | Method for synthesizing NDA and its derivatives having antioxidant activity | |
| JPH05148175A (en) | Production of p-dimethoxybenzene derivative | |
| KR101356454B1 (en) | Method for preparing unsaturated aldehyde compound | |
| CN115724729A (en) | 1-aryl-alpha, beta-unsaturated ketone compounds, synthesis method thereof and application thereof in preparation of root-knot nematode killing medicines | |
| JPH0841005A (en) | Production of 4-fluoroalkoxycynnamonitrile compound | |
| JP3918468B2 (en) | 3,3-bis (alkoxycarbonyl-methylthio) propionitrile and process for producing the same | |
| TWI435872B (en) | 2-substituted 3-arylmethylbenzofuran | |
| Baseer et al. | IN-VITRO EVALUATION OF 2’-HYDROXY CHALCONES FOR ANTIOXIDANT ACTIVITY | |
| KR20130106908A (en) | SYNTHESIS OF 4-SUBSTITUTED CHIRAL CHROMANOLS BY USING MALONIC ESTER AND O-HYDROXYAROMATIC α,β-UNSATURATED ALDEHYDES | |
| ITMI20071110A1 (en) | PROCEDURE FOR THE PREPARATION OF HYDROXYSEROSOL DERIVATIVES AND HYDROXYTIROSOL BY OXIDATIVE DEMETILATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application | St.27 status event code:A-0-1-A10-A12-nap-PA0109 | |
| PA0201 | Request for examination | St.27 status event code:A-1-2-D10-D11-exm-PA0201 | |
| D13-X000 | Search requested | St.27 status event code:A-1-2-D10-D13-srh-X000 | |
| D14-X000 | Search report completed | St.27 status event code:A-1-2-D10-D14-srh-X000 | |
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection | St.27 status event code:A-1-2-D10-D21-exm-PE0902 | |
| PG1501 | Laying open of application | St.27 status event code:A-1-1-Q10-Q12-nap-PG1501 | |
| T11-X000 | Administrative time limit extension requested | St.27 status event code:U-3-3-T10-T11-oth-X000 | |
| E13-X000 | Pre-grant limitation requested | St.27 status event code:A-2-3-E10-E13-lim-X000 | |
| P11-X000 | Amendment of application requested | St.27 status event code:A-2-2-P10-P11-nap-X000 | |
| P13-X000 | Application amended | St.27 status event code:A-2-2-P10-P13-nap-X000 | |
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration | St.27 status event code:A-1-2-D10-D22-exm-PE0701 | |
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment | St.27 status event code:A-2-4-F10-F11-exm-PR0701 | |
| PR1002 | Payment of registration fee | St.27 status event code:A-2-2-U10-U11-oth-PR1002 Fee payment year number:1 | |
| PG1601 | Publication of registration | St.27 status event code:A-4-4-Q10-Q13-nap-PG1601 | |
| FPAY | Annual fee payment | Payment date:20130226 Year of fee payment:4 | |
| PR1001 | Payment of annual fee | St.27 status event code:A-4-4-U10-U11-oth-PR1001 Fee payment year number:4 | |
| FPAY | Annual fee payment | Payment date:20131128 Year of fee payment:5 | |
| PR1001 | Payment of annual fee | St.27 status event code:A-4-4-U10-U11-oth-PR1001 Fee payment year number:5 | |
| FPAY | Annual fee payment | Payment date:20141201 Year of fee payment:6 | |
| PR1001 | Payment of annual fee | St.27 status event code:A-4-4-U10-U11-oth-PR1001 Fee payment year number:6 | |
| FPAY | Annual fee payment | Payment date:20151204 Year of fee payment:7 | |
| PR1001 | Payment of annual fee | St.27 status event code:A-4-4-U10-U11-oth-PR1001 Fee payment year number:7 | |
| P22-X000 | Classification modified | St.27 status event code:A-4-4-P10-P22-nap-X000 | |
| FPAY | Annual fee payment | Payment date:20170605 Year of fee payment:8 | |
| PR1001 | Payment of annual fee | St.27 status event code:A-4-4-U10-U11-oth-PR1001 Fee payment year number:8 | |
| FPAY | Annual fee payment | Payment date:20171207 Year of fee payment:9 | |
| PR1001 | Payment of annual fee | St.27 status event code:A-4-4-U10-U11-oth-PR1001 Fee payment year number:9 | |
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee | St.27 status event code:A-4-4-U10-U13-oth-PC1903 Not in force date:20181208 Payment event data comment text:Termination Category : DEFAULT_OF_REGISTRATION_FEE | |
| PC1903 | Unpaid annual fee | St.27 status event code:N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text:Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date:20181208 |